Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Early Data On JAK Inhibitor Show Incyte And Lilly Are In The Race In Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

It's early days in the oral RA race, but data so far suggest the Incyte/Lilly compound could hold its own against Pfizer's front-runner tasocitinib.

You may also be interested in...



Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift

Pfizer retains its lead in race to bring a novel oral RA drug to market

With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis

No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.

Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel